Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Low doses of 15d-PGJ2 induce osteoblast activity in a PPAR-gamma independent manner.

Napimoga MH, Demasi AP, Bossonaro JP, de Araújo VC, Clemente-Napimoga JT, Martinez EF.

Int Immunopharmacol. 2013 Jun;16(2):131-8. doi: 10.1016/j.intimp.2013.03.035. Epub 2013 Apr 15.

2.

15-deoxy-δ12,14-prostaglandin j2 inhibits osteolytic breast cancer bone metastasis and estrogen deficiency-induced bone loss.

Kim KR, Kim HJ, Lee SK, Ma GT, Park KK, Chung WY.

PLoS One. 2015 Apr 10;10(4):e0122764. doi: 10.1371/journal.pone.0122764. eCollection 2015.

4.

[The effect of ligand of peroxisome proliferators-activated receptor gamma 15d-PGJ2 on the proliferation and activation of hepatic stellate cells].

Yang WZ, Liu RL, Zeng MD, Lu LG, Fan ZP, Xu SC, Wang SL, Yang L.

Zhonghua Gan Zang Bing Za Zhi. 2007 Feb;15(2):114-7. Chinese.

PMID:
17362636
5.
8.
9.

Inhibition of IL-10-induced STAT3 activation by 15-deoxy-Delta12,14-prostaglandin J2.

Ji JD, Kim HJ, Rho YH, Choi SJ, Lee YH, Cheon HJ, Sohn J, Song GG.

Rheumatology (Oxford). 2005 Aug;44(8):983-8. Epub 2005 Apr 19.

PMID:
15840591
11.
12.

Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), reduce ischaemia/reperfusion injury of the gut.

Cuzzocrea S, Pisano B, Dugo L, Ianaro A, Patel NS, Di Paola R, Genovese T, Chatterjee PK, Di Rosa M, Caputi AP, Thiemermann C.

Br J Pharmacol. 2003 Sep;140(2):366-76. Epub 2003 Aug 11.

13.

Peroxisome proliferator-activated receptor-gamma agonists attenuate angiotensin II-induced collagen type I expression in adventitial fibroblasts.

Zhang J, Fang NY, Gao PJ, Wu LY, Han WQ, Guo SJ, Shen WL, Zhu DL.

Clin Exp Pharmacol Physiol. 2008 Jan;35(1):72-7.

PMID:
18047631
14.

Activation of peroxisome proliferator-activated receptor gamma inhibits TNF-alpha-mediated osteoclast differentiation in human peripheral monocytes in part via suppression of monocyte chemoattractant protein-1 expression.

Hounoki H, Sugiyama E, Mohamed SG, Shinoda K, Taki H, Abdel-Aziz HO, Maruyama M, Kobayashi M, Miyahara T.

Bone. 2008 Apr;42(4):765-74. doi: 10.1016/j.bone.2007.11.016. Epub 2007 Dec 15.

PMID:
18242157
15.

A natural PPAR-gamma agonist, 15-deoxy-delta 12,14-prostaglandin J2, may act as an enhancer of PAI-1 in human proximal renal tubular cells under hypoxic and inflammatory conditions.

Kimura H, Li X, Torii K, Okada T, Takahashi N, Fujii H, Ishihara S, Yoshida H.

Nephrol Dial Transplant. 2008 Aug;23(8):2496-503. doi: 10.1093/ndt/gfn139. Epub 2008 Mar 26.

PMID:
18367541
16.

15-Deoxy-delta 12,14-prostaglandin J2 induces apoptosis via JNK-mediated mitochondrial pathway in osteoblastic cells.

Lee SJ, Kim MS, Park JY, Woo JS, Kim YK.

Toxicology. 2008 Jun 27;248(2-3):121-9. doi: 10.1016/j.tox.2008.03.014. Epub 2008 Mar 27.

PMID:
18450357
17.

Peroxisome proliferator-activated receptor-gamma ligand, 15-deoxy-Delta12,14-prostaglandin J2, reduces neutrophil migration via a nitric oxide pathway.

Napimoga MH, Vieira SM, Dal-Secco D, Freitas A, Souto FO, Mestriner FL, Alves-Filho JC, Grespan R, Kawai T, Ferreira SH, Cunha FQ.

J Immunol. 2008 Jan 1;180(1):609-17.

18.
19.

Effect of cyclopentanone prostaglandin 15-deoxy-delta12,14PGJ2 on early functional recovery from experimental spinal cord injury.

Genovese T, Esposito E, Mazzon E, Di Paola R, Muià C, Meli R, Bramanti P, Cuzzocrea S.

Shock. 2008 Aug;30(2):142-52. doi: 10.1097/SHK.0b013e31815dd381.

PMID:
18628687
20.

Supplemental Content

Support Center